Neovacs : announces its clinical advisory board meeting to design the Phase III Study for IFNalpha Kinoide in lupus - Paris February 11th

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE

NEOVACS ANNOUNCES ITS CLINICAL ADVISORY BOARD MEETING
TO DESIGN THE PHASE III STUDY FOR IFN-K IN LUPUS

 MEETING TO BE HELD IN PARIS, FEBRUARY 11^TH

Paris and Boston, January 31^th, 2019 - 5:45 pm CET - Neovacs (Euronext Paris Growth Paris: ALNEV), leader in active immunotherapy for the treatment of auto-immune diseases, announces it has formed its Clinical Advisory Board (CAB) which will meet in Paris on the 11^th of February. Prof Frédéric Houssiau, MD, PhD (Vice-Rector of the Health Sciences Sector, at the University Catholic of Louvain, Brussels, Belgium, formerly Head of the Rheumatology Department at the Cliniques Universitaires Saint-Luc in Brussels) will chair this CAB composed of multidisciplinary international medical experts in Lupus:

• Pr Eric Morand, MD, PhD, Head of the School of Clinical Sciences at Monash Health, Monash University and Head of the Monash Health Rheumatology Unit.
• Pr Thomas Dörner, MD, Professor of Rheumatology and Hemostaseology at Charité University Hospitals, Berlin,
• Dr Katherine Thanou, MD, Research Affiliate, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, USA
• Dr Michael Tee, MD, MHPED, MBA, Vice Chancellor, Medical Center Manila, Rheumatology Department, UP Manila College of Medicine 
• Dr Edsel Maurice Salvana, MD, PhD, Director, Institute of Molecular Biology and Biotechnology, National Institutes of Health, University of the Philippines Manila, Philippines

This CAB under the Chairmanship of Pr Frédéric Houssiau will support Neovacs in the design of the Phase III study for IFN-K in Lupus, based on the results of the Phase IIb study.

About Neovacs
Listed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by four patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and also in preclinical trial for Type 1 diabetes. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr

Contacts

NEOVACS – Corporate Communication & Investor Relations
Charlène Masson
[phone]
[e-mail]

NEWCAP- Media
Annie-Florence Loyer
[phone] / + 33 6 88 20 35 59
[e-mail]
Léa Jacquin
[phone] / [phone]
[e-mail]

ORPHEON FINANCE – Financial Communication and Investor Relations
James Palmer
[phone]
[e-mail]

Attachment

• Press Release